tiprankstipranks
Qualigen Therapeutics Inc (QLGN)
NASDAQ:QLGN

Qualigen Therapeutics (QLGN) Stock Price & Analysis

541 Followers

QLGN Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.28 - $1.26
Previous Close$0.31
Volume27.12K
Average Volume (3M)66.73K
Market Cap
$1.97M
Enterprise Value$2.87M
Total Cash (Recent Filing)$400.00K
Total Debt (Recent Filing)$1.30M
Price to Earnings (P/E)-0.1
Beta0.44
May 10, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.53
Shares Outstanding6,307,371
10 Day Avg. Volume82,898
30 Day Avg. Volume66,732
Standard Deviation0.36
R-Squared0.01
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)-0.90
Price to Sales (P/S)-0.58
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.06
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.16
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

QLGN FAQ

What was Qualigen Therapeutics Inc’s price range in the past 12 months?
Qualigen Therapeutics Inc lowest stock price was $0.28 and its highest was $1.26 in the past 12 months.
    What is Qualigen Therapeutics Inc’s market cap?
    Currently, no data Available
    When is Qualigen Therapeutics Inc’s upcoming earnings report date?
    Qualigen Therapeutics Inc’s upcoming earnings report date is May 10, 2024 which is in 20 days.
      How were Qualigen Therapeutics Inc’s earnings last quarter?
      Qualigen Therapeutics Inc released its earnings results on Mar 29, 2024. The company reported -$0.466 earnings per share for the quarter, beating the consensus estimate of -$0.52 by $0.054.
        Is Qualigen Therapeutics Inc overvalued?
        According to Wall Street analysts Qualigen Therapeutics Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Qualigen Therapeutics Inc pay dividends?
          Qualigen Therapeutics Inc does not currently pay dividends.
          What is Qualigen Therapeutics Inc’s EPS estimate?
          Qualigen Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Qualigen Therapeutics Inc have?
          Qualigen Therapeutics Inc has 6,307,371 shares outstanding.
            What happened to Qualigen Therapeutics Inc’s price movement after its last earnings report?
            Qualigen Therapeutics Inc reported an EPS of -$0.466 in its last earnings report, beating expectations of -$0.52. Following the earnings report the stock price went up 5.714%.
              Which hedge fund is a major shareholder of Qualigen Therapeutics Inc?
              Currently, no hedge funds are holding shares in QLGN
              ---

              Qualigen Therapeutics Stock Smart Score

              N/A
              Not Ranked
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10

              Technicals

              SMA
              Negative
              20 days / 200 days
              Momentum
              -70.44%
              12-Months-Change

              Fundamentals

              Return on Equity
              -505.62%
              Trailing 12-Months
              Asset Growth
              -89.35%
              Trailing 12-Months

              Company Description

              Qualigen Therapeutics Inc

              Ritter Pharmaceuticals, Inc. engages in the development of novel therapeutic products which modulate the human gut microbiome to treat digestive disorders and gastrointestinal diseases. It focuses on the development and commercialization of RP-G28. The company was founded by Andrew J. Ritter and Ira E. Ritter on March 29, 2004 and is headquartered in Los Angeles, CA.
              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              Agenus
              Aptose Biosciences
              Benitec Biopharma
              Bio-Path Holdings
              Popular Stocks
              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis